Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
  • Commercial

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

BioPharma Dive

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

CommercialOncologyRead full story

pharminent April 23, 2026 (Last updated: April 24, 2026)

BioPharma Dive

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

CommercialOncologyRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sanofi posts upbeat sales as R&D pressure builds
Next: Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus

Related Stories

  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
  • Commercial

Post-marketing oncology studies: Enabling faster recruitment and lower costs

pharminent June 22, 2026
  • Commercial

The first 14 days: How specialty programs set patients up for success

pharminent June 22, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.